Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-02-12
2011-12-27
Shin, Dana (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500, C435S006100
Reexamination Certificate
active
08084432
ABSTRACT:
The present invention relates methods of treating pouchitis by administering a pharmaceutical formulation suitable for rectal use, such as an enema or suppository, comprising an antisense oligonucleotide targeted to ICAM-1 to an individual.
REFERENCES:
patent: 3687808 (1972-08-01), Merigan, Jr. et al.
patent: 4689320 (1987-08-01), Kaji
patent: 5087617 (1992-02-01), Smith
patent: 5098890 (1992-03-01), Gewirtz et al.
patent: 5135917 (1992-08-01), Burch
patent: 5166195 (1992-11-01), Ecker
patent: 5194428 (1993-03-01), Agrawal et al.
patent: 5242906 (1993-09-01), Pagano et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5286717 (1994-02-01), Cohen et al.
patent: 5514788 (1996-05-01), Bennett et al.
patent: 5543508 (1996-08-01), Haseloff et al.
patent: 5545729 (1996-08-01), Goodchild et al.
patent: 5591623 (1997-01-01), Bennett et al.
patent: 5595978 (1997-01-01), Draper et al.
patent: 5672359 (1997-09-01), Digenis et al.
patent: 5674530 (1997-10-01), Amidon et al.
patent: 5705188 (1998-01-01), Junichi et al.
patent: 5716780 (1998-02-01), Edwards et al.
patent: 5801154 (1998-09-01), Baracchini et al.
patent: 5846983 (1998-12-01), Sandborn et al.
patent: 5937862 (1999-08-01), Targan et al.
patent: 6096722 (2000-08-01), Bennett et al.
patent: 6111094 (2000-08-01), Bennett et al.
patent: 6582908 (2003-06-01), Fodor et al.
patent: 6730702 (2004-05-01), Kono et al.
patent: 7341741 (2008-03-01), Sachetto et al.
patent: 2001/0053519 (2001-12-01), Fodor et al.
patent: 2003/0228597 (2003-12-01), Cowsert et al.
patent: WO93/24510 (1993-12-01), None
patent: WO97/30731 (1997-08-01), None
Patil et al., DNA-based therapeutics and DNA delivery systems: A comprehensive review, 2005, The AAPS Journal, vol. 7, pp. E61-E77.
Patel et al., Circulating soluble adhesion molecules in inflammatory bowel disease, 1995, European Journal of Gastroenterology & Hepatology, vol. 7, pp. 1037-1041.
“Isis Pharmaceuticals Reports Financial Results and Highlights for the Year 2002”, PR Newswire, New York: Feb. 11, 2003, 11 pages of print-out version are included.
Knobler et al., Pouch Ileitis—Recurrence of the inflammatory bowel disease in the Ileal reservoir, Mar. 1986, American Journal of Gastroenterology, vol. 81, pp. 199-201.
Madden et al., Inflammation in ileal reservoirs: ‘pouchitis’, 1990, Gut, vol. 31, pp. 247-249.
Subramani et al., Refractory pouchitis: does it reflect underlying Crohn's disease? 1993, Gut, vol. 34, pp. 1539-1542.
Gewirtz et al., Alicaforsen Isis Pharmaceuticals, 2001, Current Opinion in Investigational Drugs, vol. 2, pp. 1401-1406.
Dictionary definition for “enema”, Merriam-Webster Online Dictionary, “http://www.merriam-webster.com/dictionary/enema”. Accessed on Apr. 15, 2008.
Sandborn et al., Pouchitis after ileal pouch-anal anastomosis: A pouchitis disease activity index, May 1994, Mayo Clinic Proceedings, vol. 69, pp. 409-415.
Yacyshyn et al., Dose ranging pharmacokinentic trial of high-dose alicaforsen (intracellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease, 2002, Ailmentary Pharmacology & Therapeutics, vol. 16, pp. 1761-1770.
Yacyshyn et al., The clinical experience of antisense therapy to ICAM-1 in Crohn's disease, 1999, Current Opinion in Molecular Therapeutics, vol. 1, pp. 332-335.
Karp et al., New enema treatments for inflammatory bowel disease, 1988, Digestive Diseases and Sciences, vol. 33, pp. 85S-87S.
Robertson, “Crohn's Trial Shows The Pros Of Antisense,”Nature Biotechnol. (1997) 15:209.
Genetic Engineering News, “ISIS Pharmaceuticals Demonstrates Efficacy in Chron's Disease With Its Antisense Drug,” (1997) 17:1, 34.
Svaninger, et al., “Incidence and Characteristics of Pouchitis in the Kock Continent Heostomy and the Pelvic Pouch,”Scand. J. Gastroenterol. (1993) 28:695-700.
Penna, et al., “Pouchitis After Ileal Pouch-Anal Anastomosis for Ulcerative Colitis Occurs With Increased Frequehcy in Patients With Associated Primary Sclerosing Cholangitis,”Gut(1996) 38:234-239.
Sandborn, “Pouchitis: Definition, Risk Factors, Frequency, Natural History, Classification, and Public Health Perspective,”in Trends in Inflammatory Bowel Disease, 1996, pp. 51-63.
Tremaine, et al., “Bismuth Carbomer Foam Enemas for Active Chronic Pouchitis: A Randomized, Double-Blind, Placebo-Controlled Trial,”Aliment. Pharmacol. Ther., (1997) 11:1041-1046.
Van Berge-Henegouwen, et al., “Pharmacology of Chenodeoxycholic Acid,”Gastroenterology(1977) 73:300-309.
Miyao, et al., “Stability and Pharmacokinetic Characteristics of Oligonucleotides Modified At Terminal Linkages in Mice,”Antisense Res. Dev. (1995) 5:115-121.
Takakura, et al., “Uptake Characteristics of Oligonucleotides in the Isolated Rat Liver Perfusion System,”Antisense Nucleic Acid Drug Dev. (1996) 6:177-183.
Muranishi, “Absorption Enhancers,”Crit. Rev. Ther. Drug Carrier Sys. (1990) 7:1-33.
Lee, “Mucosal Penetration Ehhancers for Facilitation of Peptide and Protein Drug Absorption,”Crit. Rev. Ther. Drug Carrier Sys. (1991) 8:91-92.
Benet, et al., “Pharmacokinetics, The Dynamics of Drug Absorption, Distribution, and Elimination,”The Pharmacological Basis of Therapeutics, 9thed., 1996. pp. 3-9.
Somogyi, et al., “Evaluation of the Intestinal Absorption of Erythromycin In Man: Absolute Bioavailability and Comparison With Enteric coated Erythromycin,”Pharm. Res. (1995) 12:149-154.
Akamo, et al., “Chemotherapy Targeting Regional Lymph Nodes by Gastric Submucosal Injection of Liposomal Adiamycin in Patients with Gastric Carcinoma,”Japan. J. Cancer Res. ( 1994) 85:652-658.
Inoue, et al., “Trial of Electrolyzed Strong Acid Aqueous Solution Lavage in the Treatment of Peritonitis and Intraperitoneal Abscess,”Artif Organs(1997) 21:28-31.
Pennington, et al., “Review Article: Artificial Nutritional Support for Improved Patient Care,”Aliment. Parmacol. Ther. (1995) 9:471-481.
Harvey, “Absorption of Drugs,”Remington's Pharmaceutical Sciences, 18thed., Chap. 35, Gennaro. ed. , Mack Pub. Co., 1990, p. 711.
Takahashi, et al., “The Use of a Perfluorochemical Emulsion As a Vascular Perfusate in Drug Absorption,”J. Pharm. Pharmacol. (1988) 40:252-257.
El-Hariri, et al., “The Mitigating Effects of Phosphatidylcholines on Bile Salt- And Lysophosphatidylcholine-Induced Membrane Dramage,”J. Pharm. Pharmacol. (1992) 44:651-654.
Yamamoto, et al., “A Mechanistic Study on Enhancement of Rectal Permeability to Insulin in the Albino Rabbit,”J. Pharm. Exp. Ther. (1982) 283:25-31.
Yamashita, et al., “Effect of Adjuvants on Charge-Selective Permeability and Electrical Resistance of Rat Jejunal Membrance.”J. Pharm. Sci. (1990) 79:579-583.
Buur, et al., “Penetration of 5-Fluorouracil and Prodrugs Across the Intestine of the Albino Rabbit: Evidence for Shift in Absorption Site From the Upper to the Lower Region of the Gastrointestinal Tract by Prodrugs,”J. Control. Rel. (1990) 14:43-51.
Yamashita, et al., “Effects of Diclofenac Sodium and Disodium Ethylenediaminetetraacetate on Electrical Parameters of the Mucosal Membrane and Their Relation to the Permeability Enhancing Effects in the Rat Jejunum,”J. Pharm. Pharmacol. (1987) 39:621-626.
Dustin and Springer, “Lymphocyte Function-Associated Antigen-1 (LFA-1) Interaction With Intercellular Adhesion Molecule-1 (ICAM-1) Is One of At Least Three Mechanisms for Lymphocyte Adhesion to Cultured Endothelial Cells,”J. Cell. Biol. (1988) 107:321-331.
Albert, et al., “Antisense Knockouts: Molecular Scalpels for the Dissection of Signal Transduction,”TIPS(1994) 15:250-254.
Kroschwitz, “Polynucleotides,”Concise Encyclopedia of Polymer Science and Engineering, Wiley & Sons, 1990, pp. 858-859.
Englisch, et al., “Ch
Miner, Jr. Philip P.
Wedel Mark K.
Isis Pharmaceuticals , Inc.
Isis Pharmaceuticals Inc. Patent Department
Shin Dana
LandOfFree
Compositions and methods for treatment of pouchitis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treatment of pouchitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of pouchitis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4308298